Introduction
============

Chinese patients have the highest HCC morbidity and mortality rates in the world, with over 75% of these patients having large nodular HCCs (diameter ≥ 5 cm)[@B1]. The management of HCC is a huge challenge due to the complicating background liver disease and the high rate of recurrence [@B2]. Many adjuvant modalities have been developed [@B3]. However, radical resection remains the most effective treatment of HCC in operable or potentially operable patients[@B4]. Although this treatment is associated with optimal prognosis, as shown by long-term survival rates, only 10-15% of patients with HCC are indicated for surgical resection[@B5]. Historically, major hepatectomy for the treatment of HCC is highly risky and frequently accompanied by surgical morbidities, especially in patients with pre-existing liver function impairment [@B6]. The remnant liver volume should be no less than 25% of the total liver volume in non-cirrhotic patients, but should be greater than 40% of the total volume in cirrhotic subjects [@B7].

Two of the determinants of surgical morbidity and patient outcome are massive bleeding during liver resection and the consequent need for blood transfusion [@B8]. Large-volume (≥ 800 mL) blood loss during resection has been reported to be an independent risk factor for postoperative morbidity, including liver dysfunction, in HCC patients with underlying liver diseases [@B9]. In addition, intraoperative transfusion has been reported associated with unfavorable prognosis in HCC patients undergoing hepatic resection, especially in patients with huge (≥ 10 cm) liver tumors [@B10]. Fortunately, the survival outcomes of East Asian patients undergoing radical resection for HCC have shown continuous improvement[@B11].

The Pringle maneuver is the standard technique used to control liver bleeding in patients undergoing hepatectomy and those with emergency liver trauma [@B12]. The primary disadvantage of this technique is the resultant ischemia-reperfusion injury, especially in cirrhotic livers less tolerant of anoxia and serum deprivation [@B13]. The Pringle maneuver is also associated with high risks of bacterial translocation, intrahepatic metastases, impaired liver regeneration, systemic inflammation, and multiple organ dysfunction syndrome [@B14]. In addition, this maneuver cannot stop bleeding from the backflow of the hepatic veins or from the inferior vena cava [@B15]. This technique has been modified to control hilar blood flow, with measures including intermittent (15 min or 30 min) occlusion, hemihepatic artery control (half-Pringle maneuver), and selective hepatic vascular exclusion for tumors involving the hepatic veins[@B16]. In addition to ischemic preconditioning, agents tested in preclinical and clinical studies include dexamethasone, dimethyl sulphoxide, somatostatin, ursodeoxycholic acid, protease inhibitor, and iNOS inhibitor[@B17].

The Glissonean pedicle transection method is a new concept of liver segmentectomy based on Glissonean pedicle tree anatomy[@B18]. The liver can be divided into three segments, left, middle, and right, as well as a caudate area, in relation to the Glissonean pedicle tree. Each segment is fed by secondary branches of the Glissonean pedicle, while the caudate area is nourished by the primary branch directly. In liver resection using the Glissonean pedicle transection method, the vessels supplying the target segment are completely ligated and divided at the hepatic hilum prior to resection without exposing the hepatic artery, portal vein, and bile duct individually. This method simplifies the procedure of liver resection, shortens operation time, and, more importantly, minimizes intraoperative bleeding. Furthermore, the use of an endolinear stapling device shortens the time required for pedicle control and expedites subsequent liver resection. This approach has been also incorporated into laparoscopic anatomical hepatectomy, showing a good feasibility and safety profile[@B19]. More promisingly, a retrospective study showed that, relative to the conventional maneuver, the Glissonean method improved the 5-year survival rates of patients undergoing hepatectomy. Since the Glissonean method also significantly reduces, diffuse-type recurrence, this method may prevent intrahepatic metastases.

Materials and Methods
=====================

Patient enrollment and assessment
---------------------------------

The study protocol was approved by the Institutional Review Board of the First Hospital of the Norman Bethune School of Medicine at Jilin University. Patients (n = 98) radiologically diagnosed with resectable primary HCC (nodular type, diameter \> 5 cm) and scheduled for radical hepatectomy *via* laparotomy were consecutively enrolled between January 2008 and May 2011. All patients underwent routine hematological, biochemical, virological serology (HBV and HCV), and serum tumor marker (alpha fetoprotein) testing at baseline screening. Chest X-rays and abdominal contrast-enhanced computed tomography scan or magnetic resonance imaging were performed to characterize the size, location, and anatomical relation of each liver tumor and to exclude any patients with radiologically detectable extrahepatic metastases. Serum albumin, total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) concentrations and prothrombin time were measured to determine the Child-Pugh score. HCC patients were eligible for radical hepatectomy via the Pringle maneuver or Glissonean pedicle transection if their preoperative indocyanine green retention rate at 15 minutes (ICG R15) was less than 10% and they preservation of at least 30% of total liver volume was expected following resection. Patients were excluded if they had extrahepatic metastases, pre-existing serious cardiovascular or cerebrovascular disease, or renal dysfunction. In addition, Patient exclusion criteria include those with tumor thrombi extending to portal bifurcation. Tumor thrombi in this area will be squeezed to other part of the liver in Glissonian approach method20. No patient exhibited ascites on preoperative abdominal ultrasonography or computed tomography. All patients provided written informed consent prior to surgery and were blinded to the method used for hilar vascular control. None of these patients received any neoadjuvant therapy. Following baseline screening, matched patients with comparable baseline characteristics were randomized 1:1 to undergo major hepatectomy using the Glissonean pedicle transection method (n = 25) or the Pringle maneuver (n = 25). All the operations as well as perioperative management were performed by a specifically designated surgical team led by a senior hepatobiliary surgeon (corresponding author) and containing resident surgeons, anesthesiologists, radiologists, pathologists, and surgical nurses. The diagnostic and management protocols complied with the updated NCCN guidelines for HCC and were approved by the Institute and the local healthcare authority. If volume of blood loss intraoperatively blood transfusion should be considered.

Major hepatectomy using the Glissonean pedicle transection method
-----------------------------------------------------------------

A laparotomy was performed through a bilateral subcostal incision. Peritoneal exploration was performed to reaffirm the resectability of the liver tumor and to exclude the presence of extrahepatic metastases and peritoneal seeding. Following liver mobilization, intraoperative ultrasonography was used to localize and characterize the liver tumor, including the number and sizes of tumors and their relationship to the vasculature. Cholecystectomy preceded the interruption of the hepatic hilum using a tourniquet. The hilar plate was dissected using Peng\'s multifunctional (\'curettage and aspiration\') operative dissector (PMOD; Shuyou Electric Science Co., Ltd., Hangzhou, China). The minor communicating vessels located inside the hilar plate were secured by cauterization. The hilar plate was further dissected downwards using a tangential clamp until reaching the posterior serosa of the hepatoduodenal ligament. The minor branches that flowed into the caudate area were appropriately preserved. In patients undergoing right or hemihepatectomy, the right or left hemihepatic pedicle, respectively was ligated using non-absorbable silk sutures (Fig. [2](#F2){ref-type="fig"}A); in patients undergoing right posterior lobectomy, the hepatic pedicles supplying the right posterior and anterior lobes were mobilized individually. The pedicle of the right posterior lobe was ligated with non-absorbable silk sutures, whereas the pedicle of the right anterior lobe was temporarily interrupted using an 8F Foley catheter. The serosal membrane covering the IVC was dissected above the renal veins and below the lower liver margin using a tangential clamp. The infrahepatic IVC was encircled using an 8F Foley catheter and appropriately fastened. The central venous pressure (CVP) was reduced to 3 cm H2O to stop the backflow of the hepatic veins into the lobe or segment intended to be removed. The liver parenchyme was transected using the PMOD along the ischemia line.

Major hepatectomy using the Pringle maneuver
--------------------------------------------

The Pringle maneuver was performed as previously described [@B21]. Briefly, the hepatoduodenal ligament was encircled using an 8F Foley catheter and retracted towards the left side (Fig. [2](#F2){ref-type="fig"}B). The infrahepatic IVC was exposed right, anterior, and inferior to the hepatoduodenal ligament, and was encircled using an 8F Foley catheter above the renal veins. The hilum was intermittently interrupted for 5 minutes initially and for 10 minutes afterwards, followed by the interruption of the infrahepatic IVC at the same intervals. Liver transection was performed using the PMOD.

Postoperative management
------------------------

Following surgery, all patients were transferred to the surgical intensive care unit (ICU) for postoperative recovery and monitoring. Discharge from the ICU was based on each patient\'s postoperative progress and was at the discretion of an independent attending ICU physician, who was blinded to the vascular control technique. Follow-up liver function tests were repeated on days 1, 5, and 10 following surgery. If ascites was suspected, diuretics were administered intravenously along with albumin supplementation, and abdominal ultrasonography or computed tomography was used to monitor the resolution of ascites. Patients were discharged from the hospital in the absence of any clinically significant events, and were followed up at 3-month intervals during the first year and at 6-month intervals thereafter. Follow-up tests included routine hematological, biochemical, and serological tests as well as abdominal CT scans.

Outcome measures
----------------

The primary outcome measure was postoperative change in liver function from baseline. The secondary outcomes included operating time, volume of intraoperative blood loss, time to resolution of ascites, tumor recurrence, and overall survival.

Statistical analysis
--------------------

Numerical data, expressed as mean ± SD, were compared in the two groups using Student-*t* tests or one-way repeated measures ANOVA. Categorical data were expressed as n (%) and were compared using Fisher\'s exact probability tests. A *P*-value less than 0.05 was considered statistically significant.

Results
=======

Baseline characteristics
------------------------

The baseline characteristics of the two groups are shown in Table [1](#T1){ref-type="table"}. The two groups were comparable in age, sex, site and size of the liver tumor, segment or lobe intended to be resected, and liver function reserve (*P* \> 0.05 each). In all patients, the remnant liver volume was expected to be \>50% of the total liver volume.

Surgical outcomes
-----------------

Following peritoneal exploration, all the patients were deemed operable and underwent successful major hepatectomies using the assigned method. No patient in the Glissonean group required conversion to the Pringle maneuver (Figure [1](#F1){ref-type="fig"}). The surgical outcomes of major hepatectomy are summarized in Table [2](#T2){ref-type="table"}. The extent of major hepatectomy was comparable in the Glissonean and Pringle groups (*P* = 0.832), including in patients undergoing right hemihepatectomy (48.0% *vs.* 46.4%, *P* = 1.000), left hemihepatectomy (40.0% *vs.* 35.7%, *P* = 0.7832), extended right hemihepatectomy (8.0% *vs.* 7.1%, *P* = 1.000), and extended left hemihepatectomy (4.0% *vs.*10.7%, *P* = 0.6127). Whereas the Glissonean approach shortened the duration of inflow control (30.0 ± 12.0 min *vs.* 45.0 ± 13.0 min, *P* \< 0.001), it failed to significantly reduce the time of liver ischemia caused by pedicular vessel control (29.0 ± 11.0 min *vs.* 34.0 ± 12.0 min, *P* = 0.122). However, blood loss from hepatectomy was significantly lower in the Glissonean than in the Pringle group (145.0 ± 20.0 mL*vs.* 298.0 ± 42.0 mL, *P* \< 0.001). None of the patients undergoing Glissonean resection required any transfusion (0.0 ± 0.0 mL*vs.* 200.0 ± 109.0 mL, *P* \< 0.001). Postoperative ascites occurred in two of the 25 patients in the Glissonean group (8.0%) and in three of 25 in the Pringle group (12.0%; P = 1.000), with approximate depths of 3.0 cm and 4.0 cm, respectively, on abdominal ultrasonography. The ascites responded well to symptomatic treatment with albumin supplementation and diuretics and resolved within 9.5 ± 1.2 d in the Glissonean group and within 15.3 ± 2.4 d in the Pringle group (*P* \< 0.001).

Postoperative liver function
----------------------------

Liver function results on days 1, 5, and 10 are shown in Figure [3](#F3){ref-type="fig"}. The two groups exhibited similar ischemia-associated liver injury following surgery, with comparable serum ALT, AST, total bilirubin, and albumin concentrations and prothrombin time over the first 10 postoperative days (*P* \> 0.05). On postoperative day 1, patients undergoing the Pringle maneuver experienced a significantly higher but transient total bilirubin concentration compared with patients undergoing the Glissonean approach (32.3 ± 3.2 μmol/L vs. 20.3 ± 3.2 μmol/L, P \< 0.001).

Surgical morbidity and mortality
--------------------------------

Most patients recovered from curative hepatectomy uneventfully regardless of the hilar control approach. The rates of clinically significant surgical morbidities were comparable inbetween the two groups (Table [3](#T3){ref-type="table"}), including rates of surgical site infection (8.0% *vs.* 8.0%, *P* = 1.000), peritoneal bleeding (0.0% *vs.* 8.0%, *P* = 0.490), and postoperative pneumonia (8.0% *vs.* 12.0%, *P* = 1.000). All these complications resolved with routine symptomatic treatment, requiring no secondary surgical intervention. No patient in either group died during hospitalization.

Follow-up and survival outcomes
-------------------------------

The patients were followed up for a mean 36.0 ± 5.6 months, with none lost to follow-up through the writing of this manuscript. The cumulative intrahepatic recurrence rates for survivors in the Glissonean and Pringle groups were 8.0% *vs.* 10.7% (*P* = 1.000) at one year, 24.0% *vs.* 28.6% (*P* = 0.763) at two years, and 48.0% *vs.* 53.6% (*P* = 0.786) at three years. Intrahepatic recurrences were controlled using transcatheter arterial chemoembolization, with or without percutaneous radiofrequency ablation. The one- and three-year overall survival rates in the Glissonean and Pringle groups were 42.3% *vs.*32.5% (*P* = 1.000) and 28.0% *vs.* 28.6% (*P* = 1.000), respectively (Fig. [4](#F4){ref-type="fig"}A), and the one- and three-year disease-free survival rates were 72.0% vs. 64.0% (P = 1.000) and 4.0% vs. 4.0% (P = 1.000), respectively (Fig. [4](#F4){ref-type="fig"}B).

Discussion
==========

The Glissonean pedicle transection method has been reported to shorten operation time, reduce intraoperative blood loss, and minimize surgical risks in HCC patients undergoing hepatectomy [@B22]. The Glissonean approach may therefore be more beneficial for HCC patients undergoing curative resection than other hilar vascular control methods such as the Pringle maneuver. However, in a large series, only 17.1% of patients underwent major hepatectomy involving two or more segments, with most patients (80.3%) undergoing segmentectomy or subsegmentectomy[@B18]. Our patient cohort differs in the extent of liver resection as well as including only patients with large (\> 5 cm) nodular HCCs. 56% Of the 25 patients in our Glissonean group, 14 (56%) underwent removal of more than 2.5 segments (right trisegmetectomy).

To our best knowledge, our study is the first to compare the surgical effectiveness and safety of Glissonean transection with the Pringle maneuver in patients with large HCC undergoing radical hepatectomy. We found that the Glissonean approach was feasible, effective, and safe for patients with large HCC and underlying liver conditions. This method yielded better recovery of liver function recovery following major hepatectomy than the conventional Pringle maneuver.

Although the Glissonean method is deemed advantageous over other hilar control methods such as the Pringle maneuver and hilar dissection, it has not been fully investigated in clinical studies, especially in head-to-head comparisons. Even some studies revealed that there were some disadvantages due to this method[@B23]. Our results are in conflict with these findings, probably due to differences in patient populations (liver metastases *versus* primary HCC), concomitant liver condition (steatosis *versus* cirrhosis), and technical modifications (combining Pringle maneuver *versus* combining partial IVC interruption). Another modification that may have contributed to the favorable outcomes in our study was our use of the \'curettage and aspiration dissection technique (CADT)\' [@B24], which is regarded as a valuable modality for segmentectomy and major hepatectomy resulting in little or no postoperative bleeding. The incorporation of this method into hilar plate dissection allowed the extra-Glisson\'s capsule *en bloc* interruption of the hepatic artery and portal vein branches flowing into the segment or lobe to be resected, rather than the individual ligation of the hepatic artery, portal vein and biliary tract. The *en bloc* interruption of Glisson\'s pedicle shortened the duration and extent of ischemia during the process of pedicle control, minimizing the adverse effects of ischemia-reperfusion injury on the patient\'s liver function, especially in patients with complicating steatosis, fibrosis, or cirrhosis. In addition, the Glissonean method reduced intraoperative blood loss, an independent risk factor for postoperative morbidity/mortality and survival in patients undergoing major hepatectomy [@B8].

Following the control of the hilum or Glisson\'s pedicle, oozing from the transected liver is derived mainly from the backflow of the hepatic veins. Although interruption of the hepatic veins has been used to further reduce blood loss from liver transection [@B25], interruption of hepatic outflow has been found to increase bleeding from the hepatectomy. Therefore, the patency of hepatic outflow is required for safe liver resection. CVP control is an effective and safe alternative to decrease backflow-associated hemorrhage [@B26]. The methods most commonly used to control CVP include the restriction of fluid infusion and the use of diuretics and/or nitroglycerin. However, these methods disturb hemodynamics and have an adverse impact on a patient\'s circulatory and renal functions. In our modified technique, the infrahepatic IVC is temporarily interrupted to reduce the CVP below 3 cmH~2~O and the resultant backflow from the retroheaptic IVC. This technique maximizes the control of hepatic vein bleeding, while having minimal effect on systemic circulation and blood electrolyte profiles. Partial interruption of the infrahepatic IVC may also be tolerated by some elderly patients.

The Glissonean method has also been associated with procedural complications and morbidities [@B27]. Dissection of the liver plate requires hepatotomy in the absence of hepatic inflow control and may cause some bleeding, although the volume is small in most patients. Dissection of the hepatoduodenal ligament may also result in iatrogenic injury to the portal vein branches flowing into the caudate lobe. In patients with biliary anatomic variations, accidental ligation of the biliary confluence can result in obstructive jaundice during early postoperative stages. Although the Glissonean approach has been reported oncologically superior to the Pringle maneuver, due to the minimized likelihood of intrahepatic metastases, our follow-up results showed that the two groups had comparable intrahepatic recurrence and survival rates. This may have been due to the more advanced tumor stage of our patients, who had larger tumors (\> 5 cm) and more frequent vascular invasion (\> 80%) as well as prevailing background cirrhosis. Advanced tumor stage has been associated with relatively poor survival (\< 30% at 3-year *vs.* \> 30% at 5-year). These pathological and oncological characteristics of Chinese HCC patients are due to endemic hepatitis B infection.

Conclusion
==========

The Glissonean pedicle transection method is a feasible, effective, and safe technique for hepatic inflow control during the curative resection of patients with large nodular HCCs. This method shortened the duration of ischemia and reduced the extent of liver parenchyme subjected to ischemia-reperfusion injury, compared with the conventional Pringle maneuver. The Glissonean method also reduced the volume of intraoperative blood loss, enhancing postoperative recovery of liver function. As an anatomical form of hepatectomy, the Glissonean method may minimize the occurrence of intrahepatic metastases, contributing to patient survival. A long-time survival follow-up study is ongoing in our institution to determine the effects on oncologic safety and survival of the Glissonean pedicle transection method in patients with large HCCs with complicating liver conditions who undergo major hepatectomy.
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Hilar interruption using the Glissonean pedicle transaction (A) and the Pringle maneuver (B): occluding the Glissonean pedicle of the left liver lobe (a), the right liver lobe (b), and the right posterior lobe (c); and occluding the liver pedicle.
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![Liver function profiles following major hepatectomy using the Glissonean pedicle transection (n = 25) or the Pringle maneuver (n = 25): (A) albumin concentration (reference, 35.0-55.0 g/L); (B) aspartate aminotransferase concentration (reference, \< 40U/L); (C) alanine aminotransferase concentration (reference, \< 40 U/L); (D) total bilirubin concentration (reference, 1.7-17.1 μmol/L); and (E) prothrombin time (reference, 9.9 - 12.8 INR).](ijmsv09p0843g04){#F3}

![Overall survival rates (A) and disease-free survival rates (B) of HCC patients undergoing major hepatectomy using the Glissonean pedicle transection (n = 25) or the Pringle maneuver (n = 25).](ijmsv09p0843g05){#F4}

###### 

Baseline characteristics of HCC patients (n = 50) scheduled for major hepatectomy.

  ------------------------------------------------------------------------------------------------------
                                        Glissonean group (n = 25)   Pringle group (n = 25)   *P*-value
  ------------------------------------- --------------------------- ------------------------ -----------
  Age, year                             55.0 ± 12.0                 58.0 ± 9.0               0.305

  Sex, M/F                              18/7                        18/7                     0.572

  Underlying liver conditions, n (%)                                                         

  *Chronic hepatitis*                   24/25 (96.0)                23/25 (92.0)             1.000

  *Liver cirrhosis*                     21/25 (84.0)                23/25 (92.0)             0.667

  *Liver steatosis*                     22/25 (88.0)                21/25 (84.0)             1.000

  Liver function reserve                                                                     1.000

  *Child-Pugh class A*                  21/25 (84.0)                22/25 (88.0)             

  *Child-Pugh class B*                  4/25 (16.0)                 3/25 (12.0)              

  ICG 15, %                                                                                  1.000

  *\<10%*                               21/25 (84.0)                22/25 (88.0)             

  *10-15%*                              4/25 (16.0)                 3/25 (12.0)              

  Laboratory values                                                                          

  *Hemoglobin, g/dL*                    13.2 ± 2.2                  12.4 ± 2.4               0.214

  *Platelet count, 10[@B9]/L*           105.2 ± 39.0                113.2 ± 37.0             0.447

  *Albumin, g/L*                        41.2 ± 11.1                 43.2 ± 11.3              0.531

  *AST, IU/mL*                          272.2 ± 112.2               287.2 ± 114.2            0.642

  *ALT, IU/mL*                          282.1 ± 118.1               292.1 ± 114.1            0.762

  *Total bilirubin, μmol/L*             22.1 ± 4.1                  24.1 ± 4.1               0.091

  *Prothrombin time, INR*               71.1 ± 16.2                 72.1 ± 16.2              0.828

  Size of tumor, cm                     8.0 ± 2.1                   7.8 ± 2.2                0.737

  Number of nodules, n                  1.2 ± 0.3                   1.3 ± 0.2                0.172

  Location of tumor, n (%)                                                                   0.625

  *Left lobe*                           7 (28.0)                    8 (32.0)                 1.000

  *Middle lobe*                         10 (40.0)                   12 (48.0)                0.776

  *Right lobe*                          8 (32.0)                    5 (20.0)                 0.520

  Number of segments involved, n (%)                                                         0.230

  *One segment*                         15 (60.0)                   19 (76)                  0.364

  *Two segments*                        8 (32.0)                    3 (12.0)                 0.171

  *Three segments*                      2 (8.0)                     3 (12.0)                 1.000

  Volume of expected remnant liver, %   50.0 ± 13.0                 50.0 ± 11.0              1.000

  Vascular involvement, n (%)\          0/25 (0.0)\                 0/28 (0.0)\              1.000\
  *Inferior vena cava*\                 18/25 (72.0%)\              21/28 (75.0)\            1.000\
  *Hepatic veins*\                      20/25 (80.0)                22/28 (78.6)             1.000
  *Portal vein*                                                                              
  ------------------------------------------------------------------------------------------------------

###### 

Surgical outcomes of patients undergoing major hepatectomy using Glissonean pedicle transection or the Pringle maneuver.

                                      Glissonean group (n = 25)   Pringle group (n = 25)   *P*-value
  ----------------------------------- --------------------------- ------------------------ -----------
  Type of resection, n (%)                                                                 1.000
  *Right hemihepatectomy*             12 (48.0)                   12 (48.0)                1.000
  *Left hemihepatectomy*              10 (40.0)                   10 (40.0)                1.000
  *Extended right hemihepatectomy*    2 (8.0)                     2 (8.0)                  1.000
  *Extended left hemihepatectomy*     1 (4.0)                     1 (4.0)                  1.000
  Overall operation time, min         80.0 ± 25.0                 100.0 ± 35.0             0.022
  *Duration of inflow control, min*   30.0 ± 12.0                 45.0 ± 13.0              \< 0.001
  *Duration of ischemia, min*         29.0 ± 11.0                 34.0 ± 12.0              0.122
  Intraoperative blood loss, mL       145.0 ± 20.0                298.0 ± 42.0             \< 0.001
  Volume of transfusion, mL           0.0 ± 0.0                   200.0 ± 109.0            \< 0.001
  Clean tumor margins, n (%)          25/25 (100.0)               25/25 (100.0)            1.000
  Tumor staging, n (%)                                                                     0.770
  *T~1~*                              6/25 (24.0)                 6/25 (24.0)              1.000
  *T~2~*                              11/25 (44.0)                12/25 (48.0)             1.000
  *T~3~*                              5/25 (20.0)                 6/25 (24.0)              1.000
  *T~4~*                              3/25 (12.0)                 1/25 (4.0)               0.609
  Newly emerging ascites              2/25 (8.0)                  3/25 (12.0)              1.000
  Time of ascites resolution, day     9.5 ± 1.2                   15.3 ± 2.4               \< 0.001
  Postoperative ICU stay, day         3.6 ± 0.8                   3.8 ± 0.7                0.352
  Postoperative hospital stay, day    12.0 ± 1.5                  14.0 ± 2.1               \< 0.001

###### 

Surgical morbidities and complications in patients undergoing major hepatectomy via Glissonean pedicle transection or the Pringle maneuver.

                                   Glissonean group (n = 25)   Pringle group (n = 25)   *P*-value
  -------------------------------- --------------------------- ------------------------ -----------
  Surgical site infections, n(%)   2/25 (8.0)                  2/25 (8.0)               1.000
  Peritoneal bleeding, n(%)        0/25 (0.0)                  2/25 (8.0)               0.490
  Postoperative pneumonia, n(%)    2/25 (8.0)                  3/25 (12.0)              1.000
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